0001104659-23-129243.txt : 20231226
0001104659-23-129243.hdr.sgml : 20231226
20231226170122
ACCESSION NUMBER: 0001104659-23-129243
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231222
FILED AS OF DATE: 20231226
DATE AS OF CHANGE: 20231226
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rubin Jonathan
CENTRAL INDEX KEY: 0001836067
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35518
FILM NUMBER: 231513892
BUSINESS ADDRESS:
BUSINESS PHONE: 3018382500
MAIL ADDRESS:
STREET 1: C/O SUPERNUS PHARMACEUTICALS, INC.
STREET 2: 9715 KEY WEST AVENUE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001356576
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9715 KEY WEST AVENUE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 301-838-2500
MAIL ADDRESS:
STREET 1: 9715 KEY WEST AVENUE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20060317
4
1
tm2333640-2_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-12-22
0
0001356576
SUPERNUS PHARMACEUTICALS, INC.
SUPN
0001836067
Rubin Jonathan
C/O SUPERNUS PHARMACEUTICALS, INC.
9715 KEY WEST AVENUE
ROCKVILLE
MD
20850
0
1
0
0
Sr. VP, Chief Medical Officer
0
Common Stock
2023-12-22
4
M
0
600
0
A
3447
D
Common Stock
2023-12-22
4
F
0
204
27.66
D
3243
D
Performance Share Unit
0
2023-12-22
4
M
0
600
0
D
Common Stock
600
0
D
Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2022.
Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022.
/s/ Timothy C. Dec, as attorney-in-fact
2023-12-26